drugset / Trial / NCT02985203
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center clinical trial, aims to evaluate the efficacy and safety of combination of oral Navelbine and Cisplatin followed by metronomic oral Navelbine in Patients with advanced Non-Small Cell Lung Cancer. The study comprises two stages. In the 1st stage (Week 1-12), all patients will receive combination chemotherapy. In the 2nd stage (Week 13-25), patients who complete the combination chemotherapy with acceptable tolerance and have no progressive disease (PD) will be allocated into 2 arms, to evaluate the efficacy and safety of maintenance chemotherapy with metronomic oral Navelbine (Arm A) or other regimen (Arm B).
Timeline
- Start
- 2016-11
- Primary completion
- 2018-04
- Completion
- 2018-04
Outcome
Outcome not reported
Stopped (Enrollment): “No participants were enrolled as schedule.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vinorelbine | Small molecule | 50 mg | Oral |
| Subject | Vinorelbine | Small molecule | 60 mg/m2 | Oral |
| Subject | Vinorelbine | Small molecule | 80 mg/m2 | Oral |